Evaluation of the Efficacy of Phospholipid-Bound Omega-3 Versus Omega-3 Alone in Patients With Hypertriglyceridemia: A Randomized Clinical Trial
Key facts
- Who runs it
- Fundación del Caribe para la Investigación Biomédica
- Where
- Colombia1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 44 people, planned
- Started
- 17 Dec 2024
- Ended
- 31 Aug 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Intervention Arm: Omega-3 + Phospholipids.
- Comparator Arm: Omega-3 alone.
- Record updated
- 17 July 2025
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (11)Hide the full registry criteria
Who can take part
- Patients aged ≥18 to 65 years
- Triglyceride levels ≥ 150 mg/dL and ≤ 500 mg/dL
- Signed informed consent
Who cannot take part
- Use of any lipid-lowering medication
- Use of substances or prescribed medications that may increase triglyceride levels (e.g., estrogens, atypical antipsychotics, etc.). -
- Known allergy to the components of the treatment
- Uncontrolled chronic diseases (e.g., renal failure, liver disease)
- Any type of cancer
- Undergoing treatment for HIV
- Use of omega-3 supplements in the last 3 months
- Pregnancy or breastfeeding
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Hypertriglyceridemia is a significant risk factor for cardiovascular diseases. Omega-3 fatty acids have been shown to reduce triglyceride levels, and their combination with phospholipids could offer additional benefits in improving lipid profiles and inflammatory markers. This study aims to evaluate the efficacy of combining omega-3 with phospholipids compared to omega-3 alone in patients with hypertriglyceridemia. The objective of the clinical trial is to provide robust evidence on the benefits of this combination in improving lipid profiles and reducing inflammation, which could have a significant impact on clinical practices and future dietary recommendations.
The 2 groups in the trial
- Group B: Comparator Arm: Omega-3 alone.Existing treatment, for comparison
Comparator Arm: Omega-3 alone
Treatment: Comparator Arm: Omega-3 alone.
- Group A: Intervention Arm: Omega-3 + Phospholipids.Treatment being tested
Intervention Arm: Omega-3 + Phospholipids.
Treatment: Intervention Arm: Omega-3 + Phospholipids.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 17 July 2025